ACTAVIS HOLDINGS UK II LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  —

  Not reported

• Net assets

  +5.6%

  £263,955,000 → £278,829,000

• Employees

  —

  Not reported

• Operating profit

  +27%

  -£26,756,000 → -£19,536,000

• Profit before tax

  -25.2%

  £21,659,000 → £16,199,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. ACTAVIS HOLDINGS UK II LIMITED 2008-03-05 → present
2. ALPHARMA HOLDINGS LIMITED 1998-04-28 → 2008-03-05

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Azets Audit Services Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors consider that preparing the financial statements on a going concern basis is appropriate due to the continued financial support of Teva Pharmaceuticals Europe B.V., a fellow group company. The directors have received confirmation from Teva Pharmaceuticals Europe B.V. that it has pledged its continuing support for a minimum of 12 months from the date of signing these financial statements.”

Significant events

• “In January 2017, Accord-UK Limited (formerly Actavis UK Limited), a direct subsidiary investment of the company, was sold to Accord Healthcare Limited for £550,900,440. As part of the sale agreement, the company agreed a number of warranties and indemnities including inter alia the UK Competition and Markets Authority ("CMA") investigation discussed below. The provision for these legal exposures increased by £19,536,000 in 2025 to £405,732,000.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.